Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Anti–Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical activity of anti–PD-1 nor the incidence of an immunoresponsive tumor microenvironment has been described for GCTs. A patient initially diagnosed with melanoma via fine needle aspiration was treated with one dose of antibody to PD-1. A core needle biopsy was subsequently performed to acquire sufficient tissue for molecular analysis, which led to a change in diagnosis to metastatic embryonal carcinoma. The testicular GCT cohort of The Cancer Genome Atlas was analyzed using a T-cell gene signature associated with benefit from immunotherapy. Primary tumors (N = 134) were categorized as high (T-cell–inflamed), medium, or low (non–T-cell-inflamed) by their T-cell signature derived from RNAseq data. Anti–PD-1 induced decreases in serum markers and a 33% reduction in tumor volume. Gene expression revealed a T-cell–inflamed tumor microenvironment in 47% of testicular GCTs, including seminoma (83%) and nonseminoma (17%) tumor subtypes. Expression of alpha-fetoprotein (AFP) RNA correlated with lack of the T-cell signature, with increasing AFP RNA inversely correlating with the inflamed signature and expression of IFNγ-associated genes. These data suggest that GCTs can respond to anti–PD-1 and that gene expression profiling supports investigation of immunotherapy for treatment of GCTs. Cancer Immunol Res; 4(11); 903–9. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Self-citationSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“A more robust approach to tumor microenvironmental evaluation may thus be facilitated by gene expression profiling where an active antitumor immune environment has been coined the "T cell–inflamed tumor microenvironment" (10).”
BackgroundFrequent PD-L1 Expression in Testicular Germ Cell Tumors
Fankhauser, C. D., Curioni-Fontecedro, A., Allmann, V, Beyer, J., Tischler, V, Sulser, T., Moch, H., & Bode, P. K. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.244 · Cited by 174 · cited 1×
“Immunohistochemical analysis for PD-L1 expression has been reported to be present in 73% of seminomas, 64% of nonseminoma, and no staining in intratubular germ cell neoplasia or normal testicular specimens (20).”
BackgroundCierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv574 · Cited by 162 · cited 1×
“The presence of PD-L1 expression by immunohistochemistry has been suggested as a prognostic marker in TGCT with a correlation between low PD-L1 expression and improved progression-free and overall survival to nonimmunotherapy interventions (21).”
Background
Cited by
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
Siska, P. J., Johnpulle, R. A. N., Zhou, A., Bordeaux, J., Kim, J. Y., Dabbas, B., Dakappagari, N., Rathmell, J. C., Rathmell, W. K., Morgans, A. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1305535 · Cited by 82
“Recent evidence suggested that evidence of T-cell activation is present in TGCT, particularly in seminomas.(12)”
BackgroundZschäbitz, S., Lasitschka, F., Hadaschik, B., Hofheinz, R.-D., Jentsch-Ullrich, K., Grüner, M., Jäger, D., & Grüllich, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.033 · Cited by 75
Lobo, J., Rodrigues, Â., Guimarães, R., Cantante, M., Lopes, P., Maurício, J., Oliveira, J., Jerónimo, C., & Henrique, R. (2019) · Cancers · doi:10.3390/cancers11101535 · Cited by 69
“explored in depth the immune infiltrate in TGCTs [16,17].”
BackgroundPembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
Tsimberidou, A.-M., Vo, H. H., Subbiah, V., Janku, F., Piha-Paul, S., Yilmaz, B., Gong, J., Naqvi, M. F., Tu, S.-M., Campbell, M., et al. (2021) · The Oncologist · doi:10.1002/onco.13682 · Cited by 43
Metadata
- Authors
- Shah, S., Ward, J. E., Bao, R., Hall, C. R., Brockstein, B. E., & Luke, J. J.
- Venue
- Cancer Immunology Research
- Published
- 2016-10-31
- Volume
- 4
- Issue
- 11
- Pages
- 903-909
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2520042661
- Cited by
- 58
- References
- 5
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. https://app.cochat.ai/papers/10.1158/2326-6066.cir-16-0087
- The paper
- Shah, S., Ward, J. E., Bao, R., Hall, C. R., Brockstein, B. E., & Luke, J. J. (2016). Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-16-0087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.